Digital Content 
NEWS #PharmaBuzz
17 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/17/2964979/0/en/Avadel-Pharmaceuticals-Announces-FDA-Approval-of-LUMRYZ-sodium-oxybate-Extended-Release-Oral-Suspension-CIII-for-the-Treatment-of-Cataplexy-or-Excessive-Daytime-Sleepiness-in-Patie.html
25 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/25/2952920/0/en/Avadel-Pharmaceuticals-Announces-Publication-of-Data-Highlighting-Efficacy-of-LUMRYZ-sodium-oxybate-Extended-Release-Oral-Suspension-in-Improving-Narcolepsy-Symptoms-Regardless-of-.html
03 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/03/2939609/0/en/Avadel-Pharmaceuticals-Announces-Publication-of-RESTORE-Data-Highlighting-Challenges-with-Twice-Nightly-Oxybates-and-Strong-Patient-Preference-for-Once-Nightly-LUMRYZ-Dosing-sodium.html
20 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/20/2932758/0/en/Avadel-Pharmaceuticals-Announces-Publication-in-Clinical-Therapeutics-of-Data-Highlighting-Weight-Loss-in-People-with-Narcolepsy-Treated-with-LUMRYZ-sodium-oxybate-Extended-Release.html
31 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/31/2922239/0/en/Avadel-Pharmaceuticals-Announces-First-Patient-Dosed-in-Phase-3-REVITALYZ-Trial-of-LUMRYZ-sodium-oxybate-Extended-Release-Oral-Suspension-for-the-Treatment-of-Idiopathic-Hypersomni.html
22 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/22/2886402/0/en/Avadel-Pharmaceuticals-Shares-New-LUMRYZ-sodium-oxybate-For-Extended-release-Oral-Suspension-CIII-Data-at-SLEEP-2024.html
Share 